Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748660 | 0.89 | HSD11B1 (0.44) | HSD11B1LOXL2HRH3NPC1RAB9A | |
| SCHEMBL3751311 | 0.89 | HSD11B1 (0.44) | HSD11B1LOXL2HRH3NPC1RAB9A | |
| SCHEMBL3751055 | 0.86 | HSD11B1 (0.57) | HSD11B1ALDH1A1 | |
| SCHEMBL3740652 | 0.85 | HSD11B1 (0.47) | HSD11B1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL4751863 | 0.85 | HSD11B1 (0.40) | HSD11B1LOXL2HRH3NPC1RAB9A | |
| SCHEMBL3736136 | 0.85 | HSD11B1 (0.47) | HSD11B1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL4751862 | 0.85 | HSD11B1 (0.40) | HSD11B1LOXL2HRH3NPC1RAB9A | |
| SCHEMBL4755819 | 0.85 | HSD11B1 (0.40) | HSD11B1LOXL2HRH3NPC1RAB9A | |
| SCHEMBL3745664 | 0.83 | MPI (0.46) | HSD11B1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL3745705 | 0.80 | HSD11B1 (0.44) | HSD11B1NPC1RAB9AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | claimed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | claimed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | claimed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1830840-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068991-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD17B10 | HSD11B1 1/4885LOXL2 1900/4885HRH3 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.